These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36245321)

  • 21. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.
    Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S
    J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
    Landau H; Wood K; Chung DJ; Koehne G; Lendvai N; Hassoun H; Lesokhin A; Hoover E; Zheng J; Devlin SM; Giralt S
    Leuk Lymphoma; 2016 Aug; 57(8):1781-5. PubMed ID: 26758672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
    Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m
    Sharma N; Benson E; Zhao Q; Nunnelee J; Cottini F; Elder P; Rosko A; Bumma N; Khan A; Umyarova E; Devarakonda S; Efebera YA; Benson DM
    Leuk Lymphoma; 2023; 64(7):1315-1321. PubMed ID: 37199099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
    Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
    Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity assessment of concurrent gabapentin/pregabalin administration with high-dose melphalan in autologous hematopoietic cell transplant recipients.
    Angus J; Cumpston A; Veltri L; Ross KG; Wen S; Dillaman M
    Support Care Cancer; 2021 Dec; 29(12):7925-7930. PubMed ID: 34191128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
    Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
    Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the adverse effects of melphalan formulations.
    Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J; Seabrook J; Fulford A; Rajakumar I
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
    Shultes KC; Arp C; Stockerl-Goldstein K; Trinkaus K; DeFrates S
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):687-693. PubMed ID: 29225163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
    Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
    Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
    Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
    Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting.
    Tan XN; Yew CY; Ragg SJ; Harrup RA; Johnston AM
    Intern Med J; 2022 Jul; 52(7):1242-1250. PubMed ID: 33949777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
    Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A
    Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation in multiple myeloma patients with renal impairment.
    Zhai Y; Yan L; Jin S; Yan S; Yao W; Shang J; Shi X; Wang R; Kang H; Lu J; Zhu Z; Tang F; Wei F; Fu C; Wu D
    Ann Hematol; 2023 Mar; 102(3):621-628. PubMed ID: 36633638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
    Miyamoto T; Yoshimoto G; Kamimura T; Muta T; Takashima S; Ito Y; Shiratsuchi M; Choi I; Kato K; Takenaka K; Iwasaki H; Takamatsu Y; Teshima T; Akashi K
    Int J Hematol; 2013 Sep; 98(3):337-45. PubMed ID: 23877150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant.
    Martino M; Gori M; Tripepi G; Recchia AG; Cimminiello M; Provenzano PF; Naso V; Ferreri A; Moscato T; Console G; Loteta B; Gallo GA; Gentile M; Innao V; Rossi M; Morabito A; Vincelli ID; Mannina D; Pitino A
    Ann Hematol; 2020 Feb; 99(2):331-341. PubMed ID: 31853703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.